Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5599 | Gap19 |
| Selective connexin 43 (Cx43) hemichannel blocker; has no effect on gap junction coupling or Panx-1 channels. Reduces mitochondrial potassium influx in cardiomyocytes and attenuates glutamate-triggered ATP release in primary astrocytes. Modestly reduces infarct size in a mouse ischemia model. | |
| BCC5603 | C34 |
| TLR4 inhibitor; attenuates TLR4 signaling in enterocytes and macrophages in vitro, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis (NEC). Also suppresses LPS signaling in human ileum displaying NEC ex-vivo. Displays no significant effects on signaling via TLR2 or TLR9. | |
| BCC5604 | ML 240 |
| ATP-competitive inhibitor of p97 ATPase (VCP, IC50 = 110 nM). Exhibits antiproliferative activity in NCI-60 cancer cell lines and rapidly induces executioner caspases 3 and 7 in multiple colon cancer cells. Promotes accumulation of LC3-II and impairs autophagosome maturation. Also impairs the endoplasmic-reticulum-associated degradation (ERAD) pathway. | |
| BCC5605 | CE3F4 |
| Noncompetitive Epac1 inhibitor. Blocks Epac-induced Rap activation and prevents isoprenaline-induced autophagy flux in cardiomyocytes. Has no effect on PKA activity in the presence of cAMP. | |
| BCC5606 | CVT 10216 |
| Potent and selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2) (IC50 values are 29 and 1300 nM for ALDH2 and ALDH1, respectively). Exhibits anxiolytic effects in rat models. | |
| BCC5607 | GSK 2837808A |
| Potent, selective lactate dehydrogenase A (LDHA) inhibitor (IC50 values are 1.9 and 14 nM for LDHA and LDHB respectively). Inhibits lactate production in selected cancer cell lines. Reduces glucose uptake and enhances mitochondrial oxygen consumption in Snu398 hepatocellular carcinoma cells. Inhibits proliferation and induces apoptosis in Snu398 cells. Inhibits transcription of histone 2B (H2B) gene in HCT116 and NCM460 cells. Cell permeable. | |
| BCC5609 | TAK 21d |
| Potent FAAH inhibitor; (IC50 values are 0.28 and 0.72 nM, at rat and human FAAH respectively). Displays analgesic effects in vivo models of neuropathic and inflammatory pain. Brain penetrant. | |
| BCC5610 | JJKK 048 |
| Potent and selective monoacylglycerol lipase (MAGL) inhibitor (IC50 = 0.4 nM). Exhibits >13,000 and ~630-fold selectivity for MAGL over FAAH and ABHD6, respectively. Increases brain levels of 2-arachidonoylglycerol (2-AG) levels in mice in vivo. Promotes analgesia in pain models. | |
